Gosuranemab, an investigational antibody against the tau protein, failed to meet its primary and exploratory efficacy goals in the TANGO Phase 2 study, its developer, Biogen, has announced. Now, the TANGO trial has been terminated and Biogen will cease the clinical development of gosuranemab as a potential therapy for Alzheimer’s disease patients, the company said. “While we are disappointed by the results of the Phase 2 study of gosuranemab, we know that the path to innovation…
You must be logged in to read/download the full post.
The post Gosuranemab Fails TANGO Trial; Biogen Stops Development appeared first on BioNewsFeeds.